J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The FDA has approved Ekterly (sebetralstat) as the first and only oral on-demand medication for acute attacks of hereditary angioedema (HAE).

Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

A discussion on formulation development, contract services, and some of the critical considerations when moving from molecule to clinic.